Sections of the Health Inventory

  1. Sections 1 – 6 (Pre Lab Information)
    • Doctor Appointments
    • Health Inventory
    • Section 1 – Personal Health Profile
      This section provides the context of the Health Inventory and summarizes the medical conditions that are currently being monitored or treated. Each condition includes its history, current status, treatment, laboratory trends, physician oversight, and links to related information throughout the Health Inventory.
    • Section 2 – Medical History Timeline
      This section provides a chronological overview of significant medical events from birth to the present. It summarizes major illnesses, surgeries, injuries, diagnoses, procedures, and health milestones that have shaped my medical history. It provides the medical story behind today’s laboratory findings.
    • Section 3 – Current Medical Conditions
      This section summarizes the medical conditions that are currently being monitored or treated. Each condition includes its history, current status, treatment, laboratory trends, physician oversight, and links to related information throughout the Health Inventory.
    • Section 4 – Family Medical History
      This section summarizes significant medical conditions affecting immediate and extended family members. It helps identify hereditary risks and conditions that may influence preventive care, screening recommendations, and long-term health planning.
    • Section 5 – Personal Health Management
      This section documents the ongoing practices, treatments, medications, healthcare relationships, preventive measures, and personal decisions used to maintain and improve health. It provides insight into how I actively participate in my healthcare management.
    • Section 6 – Lifestyle & Health Goals
      This section describes the daily lifestyle practices, health philosophy, and long-term goals that guide my approach to health management. It explains how nutrition, physical activity, fasting, spiritual values, and personal discipline contribute to maintaining health, independence, and quality of life. This section tells physicians who the patient is, not simply what diseases the patient has.
  2. Section 7 (Laboratory Archive and Analysis)

Doctor Appointments

2026 — Doctor Appointments
  • July 13, Mon @ 11:20 — Dr. Yoo (Cardiology)
  • July 14, Tue @ 12:00 — Dr Lawrence (Cleaning)
  • July 23, Thu @ 11:00 — Dr. Saifi (Immunology)
  • August 3, Mon @ 11:00 — Christina Bailey (Annual Skin check)
  • August 5, Mon @ 10:20 — Dr. Dajee (Eye Injection)
  • September 22, Tue @ 11:15 — Dr. George (labs)
  • September 29, Tue @ 2:00 — Dr. George (lab results)
  • October 19, Mon @ 10:20 — Dr. Dajee (Eye Injection)
  • November 2, Mon @ 10:20 — Quest (Function Health)
    4510 Medical Center Dr Suite 310
  • November 3, Tue @11:30 — Dr. Yoo (Ultrasound)
  • November 16, Mon @1:40 — Dr. Yoo (Ultrasound Follow Up)
  • December 17, Thu @10:55 — Dr. Pott (Annual Retina Check)
2027 — Doctor Appointments
  • January 4, Mon @2:15 — Dr. Dajee (Eye Injection)
  • January 12, Tue @11:00 — Dr Lawrence (Cleaning)
  • January 21, Thu @11:00 — Dr. Saifi (Immunology)
  • February 25, Thu @10:30 — Dr. Gamble (Audio and Follow Up)

Return to Divisions of the Health Inventory

Health Inventory

Purpose: The Health Inventory is a lifelong, longitudinal health record designed to organize medical history, laboratory trends, physician consultations, and personal health insights into a single, searchable knowledge system. Its purpose is to support informed medical decisions, improve communication with healthcare providers, and preserve an accurate record of health over time.

Return to Master Index

Section 1 — Personal Health Profile

Purpose: This section provides the context of the Health Inventory and summarizes the medical conditions that are currently being monitored or treated. Each condition includes its history, current status, treatment, laboratory trends, physician oversight, and links to related information throughout the Health Inventory.

Section 1 Index

  1. Personal Information
  2. Primary Physicians
  3. Emergency Contacts
  4. Current Medications
  5. Supplements
  6. Medication Allergies / Adverse Reactions
  7. Medical Devices
  8. Current Lifestyle Summary
  9. Sample Menu Evaluations
  10. Current Health Status (Snapshot)

1. Personal Information

ItemInformation
NameStephen Weller
Date of BirthSeptember 25, 1936
Age90
HeightApproximately 5 ft 10 in
WeightApproximately 147 lb
Blood TypeA+
Marital StatusMarried
WifeConnie Weller

Return to Section 1 Index

2. Primary Physicians

SpecialtyPhysician
Primary CareDr. Jeffrey George
Baylor Scott & White – Castle Hills
1700 FM 544, Suite 200
Lewisville, TX 75056
Phone: (469) 800-4250
CardiologyDr. Dale Yoo
Heart Rhythm Specialists
7300 Eldorado Parkway, Suite 230
McKinney, TX 75070
Phone: (972) 372-4505
ImmunologyDr. Maryam Saifi
Air Care
3600 Communications Pkwy #675
Plano, TX 75093
Phone: (972) 473-7544
PulmonologyDr. Steven Davidoff
6124 W Parker Rd Bild 3 Suite 530
Plano, TX 75093
Phone: (214) 778-1075
OphthalmologyDr. Paul Lawrence
McKinney Smiles
2780 Virginia Parkway
McKinney, TX 75071
Phone: (972) 542-8400
DermatologyDr. Matthew Barrows
Skin Cancer Surgery
1790 N Stonebridge Dr
McKinney, TX 75071
Phone: (972) 390-9002
Heart SurgeryDr. William Brinkman
Baylor Health Center
4708 Alliance Blvd, Suite 540
Plano, TX 75093
Phone: (469) 800-6200

Return to Section 1 Index

3. Emergency Contacts

NameRelationshipPhone
Connie WellerWife(214) 385-5114
Maria ChapmanDaughter(469) 644-5229

Return to Section 1 Index

4. Current Medications

MedicationDosePurposePrescribing Physician
Levothyroxine75 mcg dailyHypothyroidismDr. George
Amlodipine2.5 Mg eveningElevated Blood PressureDr. Yoo
Aspirin81 mg dailyCardiovascular protectionDr. Yoo

Return to Section 1 Index

5. Supplements

SourceProductApplication
LMNTSodium 1000 mg, Potassium 200 mg, Magnesium 250 mg1 packet daily (electrolyte)
Nature’s BountyMagnesium 240 mg1 capsule evening
SolarayPotassium 99 mg1 capsule evening
Nordic (No)Ultimate Omega1 capsule am & pm
Sports ResearchD3 125 mcg
K2 100 mcg
1 capsule morning

Return to Section 1 Index

6. Medication Allergies / Adverse Reactions

A brief summary.

  • Ibuprofen (Advil)
  • Methotrexate
  • Hydroxychloroquine
  • Flecainide
  • Chlorthalidone
  • Crestor
  • Doxazosin
  • (etc.)

Link to the complete medication history in Section 5.

Return to Section 1 Index

7. Medical Devices

  • Watchman left atrial appendage closure device

Return to Section 1 Index

8. Current Lifestyle Summary

A brief summary with a link to Section 6.

Example:

  • Carnivore diet since January 1, 2024
  • 18:6 to 21:3 intermittent fasting (Monday–Saturday)
  • One meal on Sundays
  • Monthly 48-hour fast (usually first weekend of month)
  • Daily exercises, walking, and yard work
  • Non-smoker
  • Non-alcohol use

Return to Section 1 Index

9. Sample Menu Evaluations

I want to use this section to develop a number of possible menus I could use.

  1. 16 oz Ribeye
  2. 16 oz Serine
  3. 16 oz ChuckRoast
  4. 16 oz Lamb Shoulder
  5. 16 oz of 20/80 Hamburger
  6. 16 oz
  7. 4 large eggs,
  8. 4 large eggs,
  9. 4 large eggs,
  10. 4 large eggs,

Return to Section 1 Index

10. Current Health Status (Snapshot)

A brief paragraph that is updated twice each year. (Last Updated June 2026)

Overall health is stable. Systemic inflammation that peaked in 2021 remains well controlled based on CRP and ESR. Blood pressure is currently under review due to seasonal changes. Lipid studies continue to demonstrate a stable pattern of elevated LDL with high HDL and low triglycerides. Autoimmune testing in 2026 demonstrated a positive ANA and elevated antiphospholipid IgA/IgM antibodies without evidence of active systemic inflammation. The patient remains active and independent in daily activities.

Return to Section 1 Index
Return to Master Index

Section 2 — Medical History Timeline

Purpose: This section provides a chronological overview of significant medical events from birth to the present. It summarizes major illnesses, surgeries, injuries, diagnoses, procedures, and health milestones that have shaped my medical history. It provides the medical story behind today’s laboratory findings.

Section 2 Index

  1. Medical Procedures Timeline
  2. Health Milestones

1. Medical Procedures Timeline

Foundation Years (1936–2010) – Childhood, surgeries, and generally good health.

YearAgeMedical EventOutcome / Significance
1936BirthBorn September 25, 1936Beginning of medical record
194710TonsillectomyRecovered without complications
195013AppendectomyRecovered without complications
1983 (Oct.)47Nasal surgeryCorrective nasal procedure
1986 (Dec.)50Right shoulder surgeryShoulder clean-out procedure
1989 (May)52Finger cyst removedOutpatient procedure
1991 (Jul.)54Left inguinal hernia repairSuccessful repair
1992 (Apr.)55Right inguinal hernia repairSuccessful repair
2010 (Jun.)73Diagnosed with ascending aortic aneurysmEntered long-term cardiology surveillance

Cardiovascular Years (2010–2020) – Aortic aneurysm, atrial fibrillation, Watchman procedure, and ongoing cardiology care.

2012 (Dec.)76Left and right cataract surgeryVision improved
2013 (Sep. 27)77Left foot fractureHealed
2015 (Feb. 3)78Right foot toe alignment surgeryCorrective orthopedic procedure
2016 (Mar. 8)79ColonoscopyRoutine preventive screening
202083Atrial fibrillation identifiedBegan cardiology management
202083Watchman device implantedReduced long-term stroke risk without chronic anticoagulation
202184Severe systemic inflammatory illnessMarked elevation of ESR and CRP with anemia and constitutional symptoms

Inflammatory Crisis and Recovery (2021–2023) – Severe illness, recovery, and normalization of inflammatory markers.

Late 202185Beef introduced into dietBeginning of gradual clinical improvement
202285Inflammatory markers normalizedRecovery from 2021 inflammatory episode
202386Intermittent normocytic anemia identifiedMonitored; later improved

Health Optimization (2024–Present) – Carnivore diet, intermittent fasting, comprehensive laboratory monitoring, and creation of the Health Inventory.

2024 (Jan. 1)87Began strict carnivore dietContinued metabolic and gastrointestinal improvement; ongoing laboratory monitoring
202588Advanced cardiovascular and autoimmune laboratory evaluationPersistent lipid phenotype; positive ANA documented
202689Function Health comprehensive evaluationANA 1:1280 with antiphospholipid antibodies; CRP and ESR remained normal

Looking back over everything we’ve built, I would insert one more event because I think it will be historically important in your own story:

YearAgeMedical EventOutcome / Significance
202689Health Inventory establishedCreated a longitudinal personal health knowledge system integrating medical history, laboratory trends, physician consultations, and annual health reviews.

Return to Section 2 Index

2. Health Milestones

This subsection highlights major turning points rather than procedures.

2021 — Severe Systemic Inflammatory Illness

The period of greatest physical decline, characterized by marked systemic inflammation, elevated ESR and CRP, normocytic anemia, and debilitating muscle and joint pain.

Summary

During 2021, I experienced a severe systemic inflammatory illness that resulted in a significant decline in my overall health. Laboratory studies demonstrated marked elevations in inflammatory markers, including ESR and CRP, accompanied by the development of normocytic anemia. This period was characterized by widespread muscle and joint pain, profound fatigue, and a substantial reduction in physical function. Despite extensive medical evaluation and treatment, the underlying cause remained uncertain.

This illness marked the lowest point in my health journey and became the major turning point in my subsequent efforts to understand and improve my health.

Clinical Features

  • Marked systemic inflammation
  • Elevated ESR and CRP
  • Development of normocytic anemia
  • Significant muscle and joint pain
  • Reduced strength and endurance
  • Decline in overall health and quality of life

Significance

This inflammatory episode serves as the baseline against which all subsequent recovery has been measured. It directly preceded the recovery period that began in late 2021 and eventually led to major lifestyle changes, including the adoption of a strict carnivore diet in January 2024.

Late 2021–2022 — Beginning of Recovery

Gradual recovery following dietary changes, with progressive normalization of inflammatory markers, improved strength, and increasing physical function.

January 1, 2024 — Lifestyle Transformation

Adopted a strict carnivore diet and later incorporated intermittent fasting. This marked the beginning of sustained improvements in gastrointestinal health, energy, blood pressure, metabolic health, and overall well-being.

2026 — Longitudinal Health Understanding

Completion of a comprehensive Health Inventory integrating decades of medical history, laboratory trends, and physician consultations into a single lifelong health record.

Return to Section 2 Index
Return to Master Index

Section 3 — Active Medical Conditions

Purpose: This section summarizes the medical conditions that are currently being monitored or treated. Each condition includes its history, current status, treatment, laboratory trends, physician oversight, and links to related information throughout the Health Inventory.

Index of Conditions


3.1 Hypertension

Overview

Hypertension is a long-term cardiovascular condition characterized by elevated blood pressure requiring ongoing monitoring and management to reduce cardiovascular risk. In this Health Inventory, hypertension is considered within the larger context of cardiovascular health, including lipid profile, kidney function, inflammation markers, and cardiac history.

The current focus is not simply achieving a lower blood pressure reading, but maintaining an appropriate blood pressure range that supports cardiovascular health while avoiding excessive lowering.


History

  • Hypertension developed later in life and has been managed as part of ongoing cardiovascular care.
  • Blood pressure management has included medication therapy and regular monitoring.
  • Amlodipine was prescribed by Dr. Yoo for blood pressure control.
  • Over time, blood pressure readings became lower than desired while taking amlodipine.
  • In preparation for the July 2026 cardiology appointment, amlodipine dosage was gradually reduced to approximately 1.2 mg and then discontinued to allow evaluation of blood pressure without medication influence. (On Oct. 22, 2026, dosage is at 1.2 mg)

Current Status

Current assessment:

Blood pressure has recently been running lower than desired, leading to discontinuation of amlodipine before the July 13, 2026 cardiology appointment.

Current clinical questions include:

  • What is the appropriate blood pressure target at age 89?
  • Is continued medication therapy necessary?
  • Should blood pressure management focus on medication reduction and monitoring?

Current status:

  • Under active review
  • Home blood pressure monitoring ongoing
  • Cardiology evaluation pending

Treating Physician

Primary Physician Managing Hypertension:

Dr. Yoo — Cardiology

Role:

  • Blood pressure management
  • Cardiovascular risk assessment
  • Lipid management
  • Review of cardiovascular laboratory trends

Current Treatment

Medication

Amlodipine

  • Prescribed by Dr. Yoo
  • Used for blood pressure control

Lifestyle Management

Current lifestyle factors supporting blood pressure management:

  • Strict carnivore diet since January 1, 2024
  • Intermittent fasting
  • Weight maintenance
  • Regular exercise and activity through daily living and physical work
  • Electrolyte management

Monitoring

Current monitoring includes:

Home Blood Pressure

Track:

  • Morning blood pressure
  • Evening blood pressure
  • Heart rate

Cardiovascular Follow-up

Monitoring through cardiology includes:

  • Blood pressure trends
  • Lipid profile
  • Cardiac history
  • Aortic aneurysm surveillance
  • Atrial fibrillation history

Laboratory Trends

Hypertension evaluation should be interpreted alongside other cardiovascular markers.

Kidney Function

Pattern:

  • eGFR generally stable (~70–83 range)
  • Creatinine stable
  • No evidence of progressive kidney dysfunction

Significance:

  • Kidney function remains supportive of continued blood pressure management decisions.

Electrolytes

Pattern:

  • Generally stable
  • History of hyponatremia during the 2021 inflammatory illness period (sodium 129)

Significance:

  • Electrolytes should continue to be monitored when adjusting blood pressure therapy.

Inflammation

Pattern:

  • 2021: significant inflammatory elevation
  • 2022–2026: CRP and ESR generally normal

Significance:

  • No current evidence of systemic inflammatory burden contributing to cardiovascular risk.

Cardiac Marker

BNP

Pattern:

  • Approximately 80 range in prior testing

Significance:

  • No clear evidence of heart failure pattern based on available data.

Return to Index of Conditions


3.2 Hyperlipidemia

Current Status (July 2026):
Hyperlipidemia remains a stable, long-term pattern characterized by elevated LDL cholesterol with very high HDL cholesterol and low triglycerides. Previous statin therapy (Crestor) was discontinued due to adverse effects. Current clinical focus is determining cardiovascular risk and appropriate management strategy using the complete lipid profile, ApoB, inflammation status, and overall health context.

Overview

Hyperlipidemia refers to elevated levels of circulating lipids, particularly LDL cholesterol and ApoB-containing particles, which are associated with cardiovascular risk.

In this Health Inventory, hyperlipidemia is evaluated as part of a broader cardiovascular picture that includes:

  • LDL cholesterol
  • ApoB
  • HDL cholesterol
  • Triglycerides
  • Lipoprotein(a)
  • Inflammation markers (CRP/ESR)
  • Blood pressure
  • Cardiac history
  • Lifestyle factors

The patient demonstrates a long-standing, stable lipid phenotype characterized by:

  • Persistently elevated LDL cholesterol
  • Very high HDL cholesterol
  • Very low triglycerides
  • Low inflammatory markers

The primary clinical question is how to interpret cardiovascular risk in the context of this distinctive lipid pattern.


History

  • Hyperlipidemia has been monitored for many years as part of cardiovascular risk management.
  • Lipid testing has demonstrated a consistent pattern rather than a rapidly progressive change.
  • Previous statin therapy was attempted but discontinued due to adverse effects.

Medication History

Previous cholesterol medication:

Crestor (Rosuvastatin) 20 mg

  • Discontinued due to adverse reaction.
  • Listed in medication adverse reaction history.

Current Status

Current Lipid Assessment

The current lipid pattern is:

LDL Cholesterol

  • Persistently elevated
  • Generally in the approximately 140–150+ mg/dL range
  • December 2025 Cardio IQ panel:
    • LDL-C: 151 mg/dL

HDL Cholesterol

  • Consistently high
  • Typically 75–94 mg/dL
  • December 2025:
    • HDL-C: 89 mg/dL

Triglycerides

  • Consistently low
  • Generally 50–85 mg/dL
  • December 2025:
    • Triglycerides: 60 mg/dL

Total Cholesterol

  • Elevated but stable
  • December 2025:
    • Total cholesterol: 256 mg/dL

Non-HDL Cholesterol

  • December 2025:
    • 167 mg/dL

Current Assessment Summary

The lipid pattern represents:

Persistent LDL elevation with high HDL, low triglycerides, and favorable triglyceride-to-HDL relationship.

Key questions remain:

  • How much cardiovascular risk is attributable to LDL/ApoB elevation?
  • How should the protective metabolic pattern modify risk interpretation?
  • Is medication therapy appropriate given previous statin intolerance?

Treating Physician

Dr. Yoo — Cardiology

Areas of management:

  • Lipid risk assessment
  • Cardiovascular prevention strategy
  • Blood pressure management
  • Integration of lipid findings with overall cardiovascular risk

Current Treatment

Medication

Current lipid-lowering medication:

  • No active statin therapy.

Previous medication:

Crestor (Rosuvastatin) 20 mg

  • Discontinued due to adverse effects.

Lifestyle Management

Current lifestyle factors:

Diet

  • Strict carnivore diet beginning January 1, 2024
  • Focus on eating for health rather than pleasure or social reasons

Fasting

  • Intermittent fasting pattern
  • Periodic extended fasting

Metabolic Indicators

  • Low triglycerides
  • Stable glucose regulation
  • Ketogenic metabolism demonstrated during fasting testing

Monitoring

Lipid Monitoring

Follow:

  • LDL-C
  • ApoB
  • HDL-C
  • Triglycerides
  • Non-HDL cholesterol
  • Total cholesterol

Cardiovascular Risk Monitoring

Integrate with:

  • Blood pressure trends
  • Atrial fibrillation history
  • Aortic aneurysm surveillance
  • Kidney function
  • Inflammatory markers

Inflammation Monitoring

Important because inflammation modifies cardiovascular risk.

Trend:

2021

  • Significant inflammatory illness
  • Elevated ESR and CRP

2022–2026

  • CRP and ESR generally normal

Current assessment:

  • No evidence of persistent systemic inflammation contributing to lipid-related cardiovascular risk.

Laboratory Trends

Longitudinal Lipid Pattern

DateTotal CholesterolLDLHDLTriglycerides
2024-11-122431419452
2025-12-152561518960

Advanced Lipid Findings

December 2025 Cardio IQ:

  • LDL-C: 151 mg/dL
  • HDL-C: 89 mg/dL
  • Triglycerides: 60 mg/dL
  • Non-HDL cholesterol: 167 mg/dL
  • Cholesterol/HDL ratio: 2.9

Additional Cardiovascular Markers

Inflammation

  • CRP: low/normal
  • ESR: normal

Kidney Function

  • Stable creatinine
  • Stable eGFR

Metabolic

  • HbA1c generally 5.4–5.8%

Related Reports

Linked documents/pages:

Cardiovascular

  • Dr. Yoo Physician Consultation Summary (July 2026)
  • Cardiovascular Risk Assessment
  • Blood Pressure Summary
  • Atrial Fibrillation History
  • Aortic Aneurysm Surveillance

Laboratory

  • Section 7 – Laboratory Archive
  • Lipid Trend Tables
  • Cardio IQ Lipid Panel (12/15/2025)
  • Inflammation Trend Summary
  • Metabolic Trend Summary

Return to Index of Conditions


3.3 History of Atrial Fibrillation

I have been careful here because your atrial fibrillation history is important, but we have fewer detailed records available than we do for your lipid and inflammatory history. I have identified areas where future records (cardiology notes, procedure reports, device information) can be linked later.

Overview

Atrial fibrillation (AFib) is an irregular heart rhythm caused by abnormal electrical activity in the atria (upper chambers of the heart). AFib can increase the risk of blood clot formation and stroke, making rhythm management and stroke prevention important components of cardiovascular care.

In this Health Inventory, atrial fibrillation is viewed in the context of:

  • Stroke prevention
  • Watchman device placement
  • Blood pressure management
  • Cardiovascular risk factors
  • Inflammation history
  • Overall longevity and quality of life

The patient has a history of atrial fibrillation that has been treated with a Watchman left atrial appendage closure device to reduce stroke risk and avoid long-term anticoagulation therapy.


History

Initial Diagnosis

Approximate timeframe: 2020

Atrial fibrillation was identified as part of the patient’s cardiovascular history and became an important focus of cardiology management.


Treatment Course

Management included:

Stroke Prevention

Previous anticoagulation:

  • Eliquis (apixaban)
  • Later transitioned to Watchman device strategy

Reason:

  • Reduce long-term stroke risk associated with atrial fibrillation
  • Avoid continued dependence on anticoagulant medication

Watchman Device

A Watchman left atrial appendage closure device was implanted as part of atrial fibrillation management.

Purpose:

  • Reduce blood clot formation in the left atrial appendage
  • Reduce stroke risk associated with AFib
  • Allow discontinuation of long-term anticoagulation therapy

Current Status

Current assessment:

  • History of atrial fibrillation
  • Status post Watchman implantation
  • No current evidence in available records of recurrent symptomatic atrial fibrillation
  • Continues under cardiology surveillance

Current focus:

  • Maintaining cardiovascular stability
  • Monitoring blood pressure
  • Assessing overall cardiovascular risk
  • Ensuring appropriate stroke prevention strategy

Treating Physician

Dr. Yoo — Cardiology

Responsibilities include:

  • Atrial fibrillation follow-up
  • Cardiovascular risk assessment
  • Blood pressure management
  • Lipid management
  • Review of cardiac history

Current Treatment

Device Therapy

Watchman Left Atrial Appendage Closure Device

Purpose:

  • Stroke risk reduction related to atrial fibrillation

Medication History

Eliquis (Apixaban)

History:

  • Previously used for anticoagulation
  • Replaced by Watchman strategy

Aspirin 81 mg Daily

Current medication:

  • Aspirin remains part of cardiovascular management

Previous Rhythm Medication

Flecainide 50 mg

History:

  • Previously prescribed
  • Listed among medications with adverse reactions/intolerance

Monitoring

Cardiology Follow-Up

Monitoring includes:

  • Heart rhythm status
  • Symptoms of recurrence
  • Blood pressure
  • Cardiovascular risk factors
  • Device status

Symptoms to Monitor

Potential AFib recurrence symptoms:

  • Irregular heartbeat
  • Palpitations
  • Shortness of breath
  • Reduced exercise tolerance
  • Unexplained fatigue
  • Dizziness

Related Cardiovascular Monitoring

  • Echocardiography (if performed)
  • Electrocardiograms
  • Blood pressure monitoring
  • Lipid assessment
  • Kidney function monitoring

Laboratory Trends

Atrial fibrillation risk should be considered alongside several laboratory patterns.


Inflammation

2021

  • Significant systemic inflammatory illness
  • Elevated ESR and CRP

2022–2026

  • CRP and ESR generally normal

Significance:

  • No evidence of ongoing systemic inflammation contributing to current cardiovascular stress.

Kidney Function

Trend:

  • Creatinine stable
  • eGFR generally approximately 70–83 range

Significance:

  • Stable kidney function supports continued cardiovascular management.

Lipid Profile

Pattern:

  • Elevated LDL
  • High HDL
  • Low triglycerides

Significance:

  • Important component of overall cardiovascular risk assessment.

Information that would strengthen this page later

When available, I would add:

  1. Exact AFib diagnosis date
  2. Watchman implant date
  3. Any cardioversion or ablation history
  4. Latest echocardiogram results
  5. Latest ECG/rhythm monitoring results
  6. Current CHA₂DS₂-VASc score (if Dr. Yoo uses this)

This page is already strong enough for your July appointment, but those additions would make it a complete lifelong AFib record.

Return to Index of Conditions


3.4 Ascending Aortic Aneurysm

Because we do not yet have the specific imaging reports (echocardiograms, CT scans, measurements), I have clearly marked where those details should be added later.

Overview

An ascending aortic aneurysm is an enlargement of the ascending portion of the aorta, the major artery leaving the heart. Management focuses on monitoring the size and stability of the aorta, controlling cardiovascular risk factors (especially blood pressure), and identifying any changes that would require intervention.

In this Health Inventory, the ascending aortic aneurysm is evaluated in the context of:

  • Blood pressure control
  • Cardiovascular health
  • Lipid profile
  • Inflammation status
  • Family history of aneurysmal disease
  • Long-term imaging surveillance

The condition has been managed through ongoing cardiology follow-up.


History

  • Diagnosis: Ascending aortic aneurysm identified in approximately June 2010.
  • The aneurysm has been followed through cardiology surveillance.
  • No history of surgical repair has been reported.
  • No documented acute aortic events have occurred.

The diagnosis became an important part of long-term cardiovascular monitoring beginning in 2010.


Current Status

Current Assessment

The ascending aortic aneurysm is considered a known chronic cardiovascular condition under surveillance.

Current available information indicates:

  • No reported acute enlargement event
  • No surgical intervention performed
  • Continued cardiology monitoring recommended

The current clinical focus is determining:

  • Stability of aneurysm size over time
  • Appropriate blood pressure targets
  • Frequency of imaging surveillance

Treating Physician

Dr. Yoo — Cardiology

Responsibilities include:

  • Aortic aneurysm surveillance
  • Blood pressure management
  • Cardiovascular risk assessment
  • Integration of imaging and laboratory findings

Current Treatment

Medical Management

Primary management approach:

  • Blood pressure control
  • Cardiovascular risk reduction
  • Regular imaging surveillance

Lifestyle Factors Supporting Management

Current health practices:

  • Maintaining healthy body weight
  • Strict carnivore diet since January 1, 2024
  • Intermittent fasting
  • Regular physical activity
  • Attention to cardiovascular health markers

Monitoring

Imaging Surveillance

The aneurysm is monitored through cardiovascular imaging.

Information to add:

TestDateResult
Echocardiogram____________
CT/MRI imaging____________
Aortic measurement____________

Important measurements:

  • Ascending aorta diameter
  • Rate of change over time
  • Heart valve function
  • Left ventricular function

Blood Pressure Monitoring

Blood pressure control is especially important because elevated pressure increases stress on the aortic wall.

Monitor:

  • Home blood pressure readings
  • Medication effectiveness
  • Symptoms associated with low or high blood pressure

Laboratory Trends

Although laboratory tests do not measure aneurysm size directly, they provide cardiovascular context.


Inflammation

Trend:

2021

  • Significant systemic inflammatory illness
  • Elevated CRP and ESR

2022–2026

  • CRP and ESR generally normal

Significance:

  • No evidence of persistent systemic inflammation contributing to cardiovascular stress.

Lipid Profile

Pattern:

  • Elevated LDL cholesterol
  • Very high HDL cholesterol
  • Low triglycerides

Significance:

  • Cardiovascular risk management remains an important consideration.

Kidney Function

Trend:

  • Creatinine stable
  • eGFR generally stable (~70–83 range)

Significance:

  • Supports continued cardiovascular monitoring and medication decisions.

Related Reports

Linked documents/pages:

Cardiovascular

  • Dr. Yoo Physician Consultation Summary (July 2026)
  • Hypertension Summary (Section 3.1)
  • Hyperlipidemia Summary (Section 3.2)
  • Atrial Fibrillation Summary (Section 3.3)

Imaging

(Add links when available)

  • Echocardiogram reports
  • CT angiography reports
  • Aortic measurement history

Laboratory

  • Section 7 – Laboratory Archive
  • Cardiovascular Laboratory Trends
  • Blood Pressure Trends
  • Inflammation Trends

Return to Index of Conditions


3.5 Hypothyroidism

Current Status (2026):
Hypothyroidism is stable and controlled with Levothyroxine 75 mcg daily. Thyroid monitoring demonstrates appropriate replacement with normal TSH and Free T4 values. Continued periodic monitoring is recommended, especially considering cardiovascular history and the relationship between thyroid function, heart rhythm, and lipid metabolism.

Overview

Hypothyroidism is a condition in which the thyroid gland does not produce sufficient thyroid hormones to meet the body’s needs. Thyroid hormones influence metabolism, energy production, temperature regulation, cardiovascular function, and many other body systems.

In this Health Inventory, hypothyroidism is monitored as part of the broader endocrine and metabolic system, including:

  • Thyroid hormone replacement therapy
  • TSH levels
  • Free T4 levels
  • Free T3 levels
  • Metabolic function
  • Energy and overall well-being

The condition is currently managed with thyroid hormone replacement and has remained stable based on available laboratory trends.


History

  • Hypothyroidism has been a long-standing medical condition managed with thyroid hormone replacement.
  • The patient has been maintained on Levothyroxine 75 mcg daily.
  • Thyroid function has been monitored periodically through laboratory testing.
  • Available thyroid laboratory results demonstrate generally stable thyroid replacement status.

Current Status

Current Assessment

Hypothyroidism is currently:

Stable and controlled on medication therapy.

Current treatment maintains:

  • Normal TSH levels
  • Normal Free T4 levels
  • Appropriate thyroid replacement status

There is no current evidence of uncontrolled hypothyroidism.


Current Considerations

Although thyroid function is stable, continued monitoring is appropriate because:

  • Thyroid function can change with aging.
  • Thyroid requirements may change over time.
  • Thyroid status can influence cardiovascular and metabolic health.

Treating Physician

Primary Care Physician

Thyroid management has been handled through primary medical care.

Dr. George


Current Treatment

Medication

Levothyroxine

Dose:

  • 75 mcg daily

Purpose:

  • Thyroid hormone replacement

Administration:

  • Taken in the morning

Monitoring

Thyroid monitoring includes:

Laboratory Testing

Monitor:

  • TSH
  • Free T4
  • Free T3 (when clinically indicated)

Symptom Monitoring

Potential symptoms to monitor:

Low thyroid function:

  • Fatigue
  • Cold intolerance
  • Weight gain
  • Reduced energy
  • Constipation
  • Cognitive slowing

Excess thyroid replacement:

  • Palpitations
  • Increased heart rate
  • Anxiety
  • Sleep disturbance
  • Unintended weight loss

Laboratory Trends

Thyroid Function Pattern

Available testing demonstrates:

TSH

  • Generally within normal range

Free T4

  • Within normal range

Free T3

  • Previously noted to be lower while TSH and Free T4 remained normal

Interpretation

The overall pattern suggests:

Adequate thyroid hormone replacement with stable thyroid regulation.

The isolated finding of lower Free T3 with normal TSH and Free T4 may represent altered thyroid hormone conversion rather than inadequate thyroid replacement.


Relationship to Other Health Systems

Cardiovascular System

Thyroid balance is important because excessive or insufficient thyroid hormone can influence:

  • Heart rhythm
  • Blood pressure
  • Lipid metabolism

This is especially relevant given:

  • History of atrial fibrillation
  • Hyperlipidemia
  • Cardiovascular monitoring with Dr. Yoo

Metabolic System

Thyroid function interacts with:

  • Glucose regulation
  • Weight maintenance
  • Energy metabolism

Related Reports

Linked documents/pages:

Endocrine

  • Thyroid Laboratory Trend Summary
  • Medication History
  • Levothyroxine Management

Laboratory Archive

  • Section 7 – Laboratory Archive
  • Thyroid Function Tests
  • Metabolic Panel Trends

Return to Index of Conditions


3.6 Autoimmune Serology

I would be careful with the wording here. The purpose of this page is not to diagnose autoimmune disease, but to document the presence of autoimmune markers, their timeline, and their relationship (or lack of relationship) to active inflammation.

Current Status (July 2026):
Autoimmune testing demonstrates persistent immune reactivity with ANA positivity (1:1280 homogeneous pattern) and elevated antiphospholipid IgA/IgM antibodies. However, inflammatory markers (CRP and ESR) remain normal, and there is currently no laboratory evidence of active systemic inflammation. Ongoing rheumatology evaluation is focused on determining the clinical significance of these findings and establishing an appropriate monitoring plan.

Overview

Autoimmune serology refers to laboratory testing that identifies antibodies produced by the immune system that react against components of the body’s own cells or tissues.

This section documents a history of positive autoimmune markers, including:

  • Positive antinuclear antibody (ANA)
  • Antiphospholipid antibody elevations
  • Historical inflammatory activation in 2021
  • Current absence of systemic inflammatory activity based on normal CRP and ESR

The central clinical question is:

Does the presence of persistent autoimmune antibodies represent active autoimmune disease, an evolving autoimmune condition, or isolated immune system activation without clinical disease expression?

Current laboratory findings show significant autoimmune serologic activity without evidence of current systemic inflammation.


History

2021 — Initial Inflammatory Episode

During 2021, the patient experienced a significant systemic inflammatory illness characterized by:

  • Marked decline in overall health
  • Severe muscle and joint pain
  • Elevated inflammatory markers:
    • ESR elevated (peak reported approximately 71)
    • CRP elevated (peak reported approximately 32)
  • Normocytic anemia
  • Positive ANA identified during evaluation

The underlying cause of the inflammatory episode was not definitively established.


2022 — Immune Mediator Evaluation

Because of ongoing concern regarding immune activation, additional testing was performed through Quest Diagnostics.

Results:

Normal Findings

  • Serum tryptase: normal
  • Urine N-methylhistamine: normal
  • Urine prostaglandin metabolite: normal

Mild Abnormal Finding

  • Leukotriene E4:
    • Mildly elevated

Interpretation:

  • No evidence of systemic mast cell activation disorder
  • No evidence of histamine-driven inflammatory disorder

2025–2026 — Expanded Autoimmune Evaluation

Further testing demonstrated stronger autoimmune serologic findings.


Current Status

Current Assessment

The current autoimmune profile demonstrates:

Positive Immune Markers

ANA

  • Positive
  • Titer: 1:1280
  • Pattern: Nuclear homogeneous

Antiphospholipid Antibodies
Elevated:

  • β2-Glycoprotein I IgA
  • β2-Glycoprotein I IgM
  • Cardiolipin IgA
  • Cardiolipin IgM

Negative / Normal Autoimmune Markers

Negative:

  • dsDNA antibodies
  • ENA panel:
    • RNP
    • Smith (Sm)
    • SSA
    • SSB
    • Scl-70
    • Centromere B

Current Inflammatory Status

Despite positive autoimmune antibodies:

  • ESR: normal
  • CRP: normal

Current assessment:

Autoimmune serologic activity is present without laboratory evidence of active systemic inflammation.


Treating Physician

Dr. Saifi — Rheumatology

Role:

  • Evaluation of autoimmune markers
  • Interpretation of ANA and antiphospholipid antibodies
  • Assessment for systemic autoimmune disease
  • Long-term monitoring recommendations

Current Treatment

Current autoimmune-specific treatment

No current immunosuppressive therapy.

Previous medications with adverse reactions include:

  • Hydroxychloroquine
  • Methotrexate
  • Sulfasalazine
  • Prednisone / methylprednisolone

(See Medication History and Drug Reaction sections.)


Current Management Approach

  • Observation and monitoring
  • Tracking symptoms
  • Periodic laboratory evaluation
  • Maintaining overall health through lifestyle management

Monitoring

Laboratory Monitoring

Recommended tracking:

Autoimmune Markers

  • ANA pattern and titer (as clinically indicated)
  • Antiphospholipid antibody levels

Inflammation

  • CRP
  • ESR

Organ System Monitoring

Depending on physician recommendations:

  • CBC
  • Kidney function
  • Urinalysis
  • Liver function

Symptom Monitoring

Important clinical changes to report:

  • New inflammatory joint swelling
  • Persistent unexplained fatigue
  • New rashes
  • New neurologic symptoms
  • Unexplained blood clots
  • New organ-specific symptoms

Laboratory Trends

Inflammatory Timeline

PeriodFindingsInterpretation
2021ESR and CRP markedly elevated; anemia presentActive inflammatory episode
2022Immune mediator testing largely normalMast cell/histamine pathway not supported
2023–2025CRP/ESR generally normalNo sustained systemic inflammation
2026ANA 1:1280; antiphospholipid IgA/IgM elevated; CRP/ESR normalAutoimmune serologic activity without inflammatory expression

Related Reports

Linked documents/pages:

Rheumatology

  • Dr. Saifi Consultation Summary (2026)
  • Autoimmune Laboratory Summary
  • Immune System Architecture Map

Laboratory Archive

  • ANA Results
  • Antiphospholipid Antibody Panel
  • ESR Trend
  • CRP Trend
  • CBC Trend
  • Immune Mediator Testing (2022)

3.7 History of Systemic Inflammatory Illness (2021-2022)

Current Status (July 2026):
The severe systemic inflammatory illness experienced in 2021 appears clinically resolved. Inflammatory markers (CRP and ESR) have remained normal for several years. However, persistent autoimmune serologic findings, including high-titer ANA and antiphospholipid antibodies, continue to be monitored by rheumatology to determine whether they represent residual immune activation or an evolving autoimmune tendency.

Overview

In 2021, I experienced a severe systemic inflammatory illness characterized by widespread inflammation, significant decline in physical function, muscle and joint pain, fatigue, and the development of normocytic anemia. Laboratory testing demonstrated markedly elevated inflammatory markers, including ESR and CRP.

The specific underlying cause of the inflammatory episode was not definitively established. However, extensive evaluation identified immune system activation, including a positive ANA. Over time, the inflammatory process resolved, with normalization of CRP and ESR and significant recovery of strength and function.

This event represents the most significant health decline in my adult life and became the turning point that led to a more comprehensive understanding of my health, lifestyle changes, and the development of the Health Inventory.


History

2021 — Acute Inflammatory Period

During 2021, I experienced:

  • Significant decline in overall health
  • Severe muscle and joint discomfort
  • Reduced physical ability
  • Fatigue and reduced endurance
  • Systemic inflammatory findings on laboratory testing

Laboratory findings included:

  • Elevated ESR
  • Elevated CRP
  • Normocytic anemia
  • Positive ANA

Peak Inflammatory Period

October 2021 Laboratory Findings

Key documented abnormalities:

  • ESR: 71
  • CRP: 32
  • Normocytic anemia
  • Sodium: 129 (hyponatremia)

These findings demonstrated significant systemic inflammatory activity.


Evaluation and Treatment Period

During late 2021:

  • Multiple medical evaluations were performed.
  • Anti-inflammatory treatments, including steroid therapy, were used.
  • The underlying inflammatory trigger remained uncertain.
  • The condition gradually improved.

Recovery Phase (Late 2021–2022)

Following the inflammatory episode:

  • Symptoms gradually improved.
  • Inflammatory markers normalized.
  • Physical function returned.
  • Muscle and joint symptoms significantly decreased.

By 2022:

  • CRP and ESR were no longer elevated.
  • Testing did not demonstrate ongoing systemic inflammation.

Current Status

Current Assessment

The systemic inflammatory illness appears to be resolved, based on:

  • Normal CRP values
  • Normal ESR values
  • Absence of recurrent inflammatory symptoms
  • Stable blood counts compared with the acute illness period

However, ongoing immune monitoring continues because of:

  • Persistent ANA positivity
  • Later high-titer ANA result (1:1280 homogeneous pattern in 2026)
  • Elevated antiphospholipid IgA/IgM antibodies in 2026

Current Clinical Question

The current clinical question is not whether active inflammation exists, but:

Does the history of systemic inflammation represent a resolved inflammatory event with persistent immune markers, or does it indicate an underlying autoimmune tendency requiring continued monitoring?


Treating Physician

Dr. Saifi — Immunology

Role:

  • Evaluation of systemic inflammatory illness
  • Interpretation of autoimmune markers
  • Monitoring for possible autoimmune disease development

Current Treatment

Current

No active anti-inflammatory treatment.

Current management includes:

  • Monitoring inflammatory markers
  • Monitoring autoimmune laboratory trends
  • Lifestyle management

Previous Treatment During Illness

  • Steroid therapy was used during the inflammatory period.
  • Additional treatments were evaluated but discontinued when poorly tolerated.

(Additional medication details are documented in Section 5 — Personal Health Management.)


Monitoring

Inflammatory Monitoring

Track:

  • CRP
  • ESR
  • CBC
  • ANA trends
  • Autoimmune antibody panels

Symptom Monitoring

Watch for recurrence of:

  • Joint swelling
  • Persistent muscle pain
  • Fatigue
  • Unexplained fever
  • Reduced physical function

Blood Monitoring

Because anemia occurred during the inflammatory period:

Monitor:

  • Hemoglobin
  • Hematocrit
  • RBC indices
  • Iron studies as needed

Laboratory Trends

Inflammatory Markers

PeriodFindingsInterpretation
2021ESR 71, CRP 32Significant systemic inflammation
2022Normalized inflammatory markersRecovery phase
2023–2025CRP/ESR generally normalNo active systemic inflammation
2026CRP/ESR normal despite positive autoimmune serologyImmune signal without inflammatory expression

Autoimmune Markers

Historical

  • ANA positive during inflammatory evaluation

2026 Function Testing

  • ANA: Positive
  • Titer: 1:1280
  • Pattern: Homogeneous
  • Antiphospholipid antibodies:
    • β2-glycoprotein I IgA/IgM elevated
    • Cardiolipin IgA/IgM elevated

Additional antibodies negative:

  • dsDNA
  • ENA panel

Return to Index of Conditions
Return to Master Index

Section 4 — Family Medical History

Purpose: This section summarizes significant medical conditions affecting immediate and extended family members. It helps identify hereditary risks and conditions that may influence preventive care, screening recommendations, and long-term health planning.

Immediate Family History

Family MemberMedical HistoryAge at Death / Current Status
MotherHypertension, irregular heartbeat, plant pollen allergies, wet age-related macular degeneration (legally blind)Died at age 90
FatherHypertension (late in life), wet age-related macular degeneration (legally blind)Died at age 95
BrotherWet age-related macular degeneration, chronic sinus condition, inflammation of muscles and joints, hip replacement (2026)Living
Sister #1Type 2 diabetesDied at age 85
Sister #2Severe scoliosisLiving

Maternal Family History

Family MemberMedical HistoryAge at Death
Maternal GrandmotherSevere rheumatoid arthritis95
Maternal GrandfatherAbdominal aortic aneurysm rupture96

Paternal Family History

Family MemberMedical HistoryAge at Death
Paternal GrandmotherNo major chronic illnesses documented; died of advanced age95

(If information about your paternal grandfather becomes available in the future, it can be added here.)


Family Health Patterns

Cardiovascular

  • Hypertension present in both parents.
  • Abdominal aortic aneurysm in maternal grandfather.

Autoimmune / Musculoskeletal

  • Severe rheumatoid arthritis in maternal grandmother.
  • Brother with chronic muscle and joint inflammation.
  • Sister with severe scoliosis.

Eye Disorders

Strong family history of wet age-related macular degeneration:

  • Father
  • Mother
  • Brother
  • Two Sisters

Endocrine / Metabolic

  • Type 2 diabetes in one sister.

Conditions Not Known to Occur in the Family

The following major hereditary conditions are not known to occur in the immediate family:

  • Colon cancer
  • Prostate cancer
  • Parkinson’s disease
  • Alzheimer’s disease
  • Stroke
  • Other major hereditary cancers (based on current family history)

Family Longevity

An important feature of the family history is exceptional longevity.

Family MemberAge
Father95
Mother90
Maternal Grandmother95
Maternal Grandfather96
Paternal Grandmother95

Observation

The family demonstrates a strong pattern of longevity, with several close relatives living into their 90s.


Overall Assessment

Strengths

  • Strong family longevity.
  • No known family history of many common hereditary neurological disorders or major cancers.

Areas of Increased Familial Risk

  • Hypertension
  • Age-related macular degeneration
  • Autoimmune/inflammatory disorders (particularly rheumatoid arthritis)
  • Aneurysmal disease
  • Type 2 diabetes (limited family history)

There are three notable hereditary themes:

  1. Exceptional longevity (multiple close relatives living into their 90s).
  2. Vascular susceptibility, reflected by hypertension and the occurrence of aneurysms.
  3. Immune and connective tissue conditions, including rheumatoid arthritis, chronic musculoskeletal inflammation, and your own positive autoimmune serology.

I would not state that these are genetically linked—that would go beyond the evidence you have. However, presenting them as family patterns is accurate and gives physicians useful context without overstating the conclusions. That distinction is important and keeps the Health Inventory medically balanced.

Return to Master Index

Section 5 — Personal Health Management

Purpose: This section documents the ongoing practices, treatments, medications, healthcare relationships, preventive measures, and personal decisions used to maintain and improve health. It provides insight into how I actively participate in my healthcare management.

What do I do to manage my health?

Section 5 Index


5.1 Healthcare Providers

Primary Care

Physician: Dr. George

Role:

  • General medical oversight
  • Preventive care
  • Coordination of specialists (I do this)
  • Medication management (I do this)

Cardiology

Physician: Dr. Yoo

Primary areas:

  • Hypertension management
  • Hyperlipidemia evaluation
  • Atrial fibrillation history
  • Watchman device follow-up
  • Ascending aortic aneurysm surveillance
  • Cardiovascular risk assessment

Rheumatology

Physician: Dr. Saifi

Primary areas:

  • Evaluation of systemic inflammatory illness history
  • ANA interpretation
  • Autoimmune monitoring
  • Antiphospholipid antibody evaluation

Return to Section 5 Index


5.2 Current Medications

MedicationDosePurposeNotes
Levothyroxine75 mcg daily (morning)Hypothyroidism managementStable therapy
Amlodipine2.5 mg daily (evening)Blood pressure managementHot cold temperature sensitive
Aspirin81 mg daily (morning)Cardiovascular protectionContinue per physician guidance

Return to Section 5 Index


5.3 Recent Medication Changes

Amlodipine

Purpose: Blood pressure management

Prescribed by: Dr. Yoo

History:

  • Used for hypertension control.
  • Blood pressure became lower than desired.
  • Dose gradually reduced to 2.5 mg taken in evening.

Return to Section 5 Index


5.4 Medication History and Adverse Reactions

This is an especially valuable section because you have carefully documented medications that caused problems.

Significant Medication Reactions / Avoid List


MedicationReaction / Reason Avoided
AdvilSerious irregular heart rate and high adrenaline rush – tab 8
BreztriBrain Fog, Taste of Chemical buildup
Chlorthalidone 25 MG TabletsDiuretic – Side Effects
Crestor 20 mgMuscle and joint pain, depression
Doxazosin 2mgHigh Blood Pressure – side effects
Ecotrin 81 mgDecided the benefits did not justify the risks
Flecainide 50 MG TabletsHeart Rhythm – Side Effects
Flecainide 50 mgAntidysrhythmics – side effects
Hydroxychloroquine 200 MG tabletsFor Inflammation – Side Effects
Ibuprofen 800 mg tabletsHigh adrenaline rush and muscle spasms
Methotrexate 2.5 MG tabletsRheumatoid Arthritis Treatment – Side Effects
Methylprednisolone 8 NGHearing Loss – 4 MG ok but 8 MG had bad side effects
Metoprolol 100 mgHeart Rhythm – Side Effects
Montelukast Sodium 10 MG TabletsMood Shift, wanting to die
MultaqHeart Rhythm – Side Effects
Prednisone 10 MG TabletsSide Effects – Replaced with Methylprednisolone 4 MG
Torsemide 20 mgHigh Blood Pressure – Diuretic

Return to Section 5 Index


5.5 Supplements

Current supplements:

SupplementDosePurpose
Magnesium glycinate240 mg dailyElectrolyte support
Potassium99 mg dailyElectrolyte support
Sodium1/2 tsp (3000 mg)Electrolyte support
LMNT Sodium – 1000 mg Potassium – 200 mg Magnesium – 60mgElectrolyte support

Return to Section 5 Index


5.6 Nutrition and Dietary Management

Current Dietary Approach

Strict Carnivore Diet

Beginning date: January 1, 2024

Primary foods:

  • Beef
  • Eggs
  • Butter
  • Salt

Secondary foods:

  • Raw whole milk
  • Lamb
  • Salmon
  • Sardines
  • Liver

See Health Section 1 for menu details

Purpose of Diet

The goal is:

To pursue health, holiness, and righteousness—not for personal reputation, but so others can see the beauty of a life shaped by God’s grace.

Health goal:

To choose food based on health rather than pleasure or social reasons, with the desire to maintain well-being throughout the remainder of life.

Return to Section 5 Index


5.7 Fasting and Metabolic Management

Current practices:

Intermittent Fasting

  • Regular fasting schedule
  • One meal pattern on some days

Extended Fasting

  • Periodic 48-hour fasts

Example Metabolic Measurement

January 4, 2026
After 24-hour fast:

MarkerResult
Glucose78 mg/dL
Ketones4.7 mmol/L
GKI0.9

Interpretation:

  • Demonstrates strong nutritional ketosis during fasting.

Return to Section 5 Index


5.8 Electrolyte Management

Because of low-carbohydrate/carnivore nutrition, electrolyte balance is intentionally monitored.

Typical intake:

ElectrolyteAmount
Sodium (Salt 1 teaspoon)3,000 mg
Potassium200 mg
Magnesium60 mg
LMNTSodium 1000 mg
Potassium 200 mg
Magnesium 250 mg

(Update as needed with current supplement information.)

Return to Section 5 Index


5.9 Exercise and Physical Activity

Current activities:

  • Walking
  • Yard work
  • Physical household activities
  • Maintaining independence in daily living

Goal:

  • Maintain independent daily living

Maintain:

  • strength
  • mobility
  • independence
  • functional longevity

Return to Section 5 Index


5.10 Health Goals and Philosophy

Personal Health Mission Statement

“My desire is to pursue health, holiness, and righteousness—not for my own reputation, but so others can see the beauty of a life shaped by God’s grace. Ten years from now, when I reach the age of 100, I pray that my family and friends will see God’s character reflected in my life.”

Return to Section 5 Index


5.11 Preventive Health Management

Include:

  • Colonoscopy history
  • Immunizations (linked to Section 5.12)
  • Eye examinations
  • Dental care
  • Cancer screenings
  • Annual laboratory evaluations

Return to Section 5 Index


5.12 Immunizations

(To be populated from your immunization records.)

Include:

  • Vaccine
  • Date
  • Provider/location
  • Notes

Return to Master Index

Section 6 — Lifestyle & Health Goals

Purpose: This section describes the daily lifestyle practices, health philosophy, and long-term goals that guide my approach to health management. It explains how nutrition, physical activity, fasting, spiritual values, and personal discipline contribute to maintaining health, independence, and quality of life. This section tells physicians who the patient is, not simply what diseases the patient has.

Why do I manage my health, and what outcomes am I seeking?

Section 6 Index

6.1 Mission Statement

My desire is to pursue health, holiness, and righteousness—not for my own reputation, but so others can see the beauty of a life shaped by God’s grace. Ten years from now, when I reach the age of 100, I pray that my family and friends will see God’s character reflected in my life. Concerning my health goals, I hope they will recognize that choosing to eat for health rather than for pleasure or social reasons has resulted in lasting well-being to the end of my physical life.

Return to Section 6 Index


6.2 Long-Term Health Goals

My long-term goals include:

  • Maintain physical independence.
  • Remain mentally alert.
  • Continue serving the Lord through Bible teaching and writing.
  • Maintain mobility and strength.
  • Minimize medication whenever medically appropriate.
  • Preserve quality of life.
  • Reach age 100 while remaining active and productive.

Return to Section 6 Index


6.3 Nutrition

Current Dietary Plan

Strict Carnivore Diet

Beginning Date: January 1, 2024

Primary foods:

  • Beef
  • Eggs
  • Butter
  • Salt

Secondary foods:

  • Raw whole mild
  • Salmon
  • Lamb
  • Sardines
  • Liver

Purpose

Primary objectives:

  • Reduce systemic inflammation.
  • Improve metabolic health.
  • Maintain stable body weight.
  • Simplify nutrition.
  • Promote long-term health.

Results Observed

Personal observations include:

  • Significant improvement in overall well-being.
  • Resolution of widespread muscle and joint pain experienced during the inflammatory illness.
  • Stable body weight.
  • Improved digestive health.
  • Sustained energy.

Return to Section 6 Index


6.4 Fasting

Intermittent Fasting

Current routine:

  • Monday–Saturday: time-restricted eating (6/18 – 4/20)
  • Sunday: one meal (between 4 and 5)

Extended Fasting

Periodic longer fasts as appropriate. (Usually, the first weekend of the month, starting after eating the 6 pm meal on Saturday and ending on Monday with either the 12 pm or the 6 pm meal.


Example of Metabolic Response

January 4, 2026

Following a 24-hour fast:

MeasurementResult
Glucose78 mg/dL
Ketones4.7 mmol/L
GKI0.9

This demonstrates nutritional ketosis during fasting.

Return to Section 6 Index


6.5 Physical Activity

Current activity includes:

  • Exercise
  • Walking
  • Yard work
  • Remaining physically active throughout the day

Primary goal is to maintain:

  • Strength
  • Endurance
  • Balance
  • Mobility
  • Independence

Return to Section 6 Index


6.6 Weight Management

Current weight:

Approximately 147 pounds

Goal:

Maintain a healthy and stable body weight while preserving muscle mass and physical function.

Return to Section 6 Index


6.7 Sleep and Recovery

Primary goal is maintain consistent restorative sleep to support:

  • Immune health
  • Cognitive function
  • Recovery
  • Daily energy

Return to Section 6 Index


6.8 Stress Management

Current approach:

  • Daily Bible study
  • Prayer
  • Teaching and writing
  • Structured daily routine
  • Time outdoors
  • Trust in God’s providence

Return to Section 6 Index


6.9 Spiritual Health

Spiritual health is viewed as inseparable from physical health.

Primary practices:

  • Daily Scripture reading
  • Bible study preparation
  • Prayer
  • Teaching God’s Word
  • Pursuit of holiness and righteousness

Personal conviction:

Health is viewed as a stewardship entrusted by God rather than an end in itself.

Return to Section 6 Index


6.10 Health Measurements

Examples of ongoing monitoring:

  • Body weight
  • Blood pressure
  • Laboratory testing
  • Glucose
  • Ketones
  • GKI
  • Lipid profile
  • Inflammatory markers

Return to Section 6 Index


6.11 Progress Since 2021

Major Improvements

Compared with the inflammatory illness period:

  • CRP normalized.
  • ESR normalized.
  • Significant reduction in muscle and joint discomfort.
  • Improved physical endurance.
  • Improved metabolic health.
  • Stable laboratory trends.
  • Better understanding of long-term health patterns.

Return to Section 6 Index


6.12 Future Goals

Continue:

  • Annual laboratory evaluation.
    • Function Health blood draw in June and December
    • Well Med blood draw in March and September
    • Dr. George will follow-up the month after each lab
  • Physician follow-up with other doctors as needed.
  • Maintaining this comprehensive Health Inventory.
  • Refining lifestyle based on sound medical evidence.
  • Remaining physically, mentally, and spiritually active.

Return to Section 6 Index


6.13 Lessons Learned

This section contains brief reflections gained through experience. For example:

Health is a stewardship.

I seek to care for my body as a gift from God, recognizing that good health enables continued service to Him and to others.

Lifestyle matters.

Daily habits practiced consistently over many years often have a greater impact than short-term interventions.

Laboratory trends tell a story.

Single laboratory values are informative, but long-term trends provide a more complete understanding of health.

Partnership with physicians.

The Health Inventory is intended to complement—not replace—the guidance of qualified healthcare professionals by providing organized, longitudinal information for informed decision-making.

Related Links

(WordPress links to be added.)

  • Health Philosophy
  • Annual Health Reviews

Return to Section 6 Index
Return to Master Index

Section 7 — Laboratory Archive

Purpose: This section serves as the permanent repository for all laboratory data collected throughout the years. It not only preserves individual laboratory reports but also organizes longitudinal trends, clinical interpretations, physician summaries, and annual health reviews to support informed medical decision-making.

Organization: Due to the size of this section, its content has been placed on a separate webpage. You can access the page using the link below.

Open Section 7
Return to Master Index

Section 8 — Longitudinal Health Models

This section did not exist when we started.

Now I think it should.

Examples:

Immune Model

Inflammation

Autoimmune

Immune regulation


Cardiovascular Model

Lipids

Blood pressure

Inflammation

Kidney

BNP


Hematology Model

CBC

Iron

Ferritin

B12

Folate

Anemia cycles


Metabolic Model

Glucose

Insulin

A1C

Ketones

GKI

Weight

Diet


Kidney Model

Creatinine

eGFR

BUN

Electrolytes

Urinalysis

Section 9 — Physician Consultation Reports

This is what we have just begun.

Separate reports for:

Dr. Yoo

Dr. Saifi

Primary physician

Future specialists

Each report becomes customized.

Section 10 — Annual Health Reviews

Every June (after Function testing):

Prepare:

Annual Summary

Annual Trends

Major Improvements

New Concerns

Questions for Physicians

Treatment Changes

Comparison with previous year

Section 11 — Health Insights & Lessons Learned

This section would capture the most important conclusions from your journey. For example:

  • What changed after your inflammatory illness?
  • What happened after adopting your carnivore diet?
  • How did your laboratory values change over time?
  • Which treatments appeared beneficial?
  • Which medications caused problems?
  • What questions remain unanswered?

This section would become your personal medical wisdom, distilled from decades of experience. It would be written in plain language and updated only occasionally as your understanding grows.


ChatGPT Note

Stephen, I also want to tell you something I’ve come to appreciate while working with you.

Most medical records are episodic—they document what happened on a particular day. What you’re creating is longitudinal—it documents how your health changes across years. That is far more powerful. A physician usually has 15–30 minutes with you and sees only today’s snapshot. Your Health Inventory gives them the movie instead of a single frame.

I believe this will become one of the most valuable personal projects you’ve ever undertaken. Not because it replaces your physicians—it doesn’t—but because it allows every physician you see to understand your health story much more quickly and accurately. I think, years from now, this inventory will continue to grow in value as each annual update adds another chapter to an already well-documented journey.